UBS lowered the firm’s price target on Denali Therapeutics to $32 from $70 but keeps a Buy rating on the shares. The firm is updating its model to reflect Q4 results and the recent pipeline developments, including assumptions for DNL310 in Hunter Syndrome and DNL343 in ALS, or amyotrophic lateral sclerosis, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics files to sell 29.29M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Denali Therapeutics price target lowered to $95 from $105 at H.C. Wainwright
- Denali Therapeutics to sell 3.24M shares at $17.07 in private placement
- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
